Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

This article was updated at 1 p.m. ET  to include new information about the lawsuit against the NIH. | A new initiative ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...

The FDA is getting the word out on a high-risk issue related to artery-clearing catheters from BD’s Bard Peripheral Vascular ...

Tasso, the maker of at-home blood sample collection systems, is launching the next generation of its devices that aim to support patients enrolled in clinical trials and simplify their pa | Its ...

Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

After China placed Illumina on a government watchlist this week, in response to new tariffs imposed by the Trump ...